Language: BG BG
nav.cta
Търсене, моля изчакайте...
Филтри
Статус
Фаза
Цел
Пол
Възраст
Държава
Филтри
Статус
Фаза
Цел
Пол
Възраст
Държава
AI · cancer
Намерени 1,748 изпитвания за "cancer" Стр. 38 от 88
Recruiting Phase 3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation HER2- Negative Breast Cancer Hormone Receptor Positive Tumor Breast Cancer +2

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.

Начало: 26.08.2025 Край: 31.12.2031 Възраст: от 18 г. Treatment
Australia, Belgium, Brazil +14 Relay Therapeutics, Inc. NCT06982521
Recruiting
Ovarian Tissue Cryopreservation Combined With Oocyte Cryopreservation Versus Oocyte Cryopreservation Alone
Oncological Disease Fertility Preservation

Fertility preservation is a crucial aspect of care for oncological patients undergoing gonadotoxic treatments such as chemotherapy, radiotherapy, or surgery, which can significantly reduce ovarian reserve and cause infertility or premature menopause. Among available techniques, oocyte cryopreservation is well-established with high survival rates but requires controlled ovarian stimulation and may not be suitable for prepubertal patients or those needing urgent cancer therapy. Ovarian tissue cryopreservation offers advantages by preserving a larger number of primordial follicles, can be performed anytime in the menstrual cycle regardless of age, and also helps restore ovarian endocrine function. Combining ovarian tissue cryopreservation followed by oocyte cryopreservation may maximize fertility preservation by safeguarding more follicles and ensuring availability of mature oocytes. This study will collect data from two patient groups: Group 1: patients undergoing ovarian tissue cryopreservation followed by oocyte cryopreservation (combined treatment) Group 2: patients undergoing oocyte cryopreservation alone. Group assignment is based on planned gonadotoxic therapy and available time before treatment initiation, according to clinical practice. The study aims to compare the number of oocytes retrieved per ovarian stimulation cycle between the two groups, along with the oocyte retrieval rate (number of oocytes retrieved/number of aspirated follicles), number of mature oocytes (metaphase II), incidence of moderate ovarian hyperstimulation syndrome within 7 days post-retrieval, and correlations between serum estradiol and luteinizing hormone levels on trigger day and oocyte yield. Approximately 127 patients aged 18 to 46 will be consecutively enrolled at the UO Gynecology and Human Reproduction Pathophysiology, IRCCS AOUBO Policlinico di Sant'Orsola. This is a cross-sectional, single-center, observational study with both retrospective and prospective enrollment. The retrospective period considered is from January 1, 2022, to the study start date. The study duration is 4 years and 3 months.

Начало: 25.08.2025 Край: 01.09.2029 Възраст: 18–46 г.
Italy IRCCS Azienda Ospedaliero-Universitaria di Bologna NCT07546123
Recruiting Phase 3
PSMA PET Combined With MRI for the Detection of PCa
PCA Prostate Cancer Prostatic Neoplasm PSMA PET +5

This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prostate cancer (PCa).

Начало: 18.08.2025 Край: 01.11.2026 Възраст: от 18 г. Diagnostic
Australia Telix Pharmaceuticals (Innovations) Pty Limited NCT07052214
Recruiting Phase 3
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Small-cell Lung Cancer Extensive Stage Small-cell Lung Cancer

The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).

Начало: 18.08.2025 Край: 15.07.2029 Възраст: 18–99 г. Treatment
Argentina, Australia, Austria +22 Amgen NCT07005128
Recruiting Phase 2
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer

This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of various treatment combinations. This study will be conducted in approximately 80 centers globally across 10 countries.

Начало: 07.08.2025 Край: 06.04.2029 Възраст: от 18 г. Treatment
Australia, Canada, China +6 AstraZeneca NCT07098338
Recruiting Phase 1
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Advanced Solid Tumor Advanced Breast Cancer Advanced Ovarian Cancer

The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.

Начало: 01.08.2025 Край: 14.12.2028 Възраст: от 18 г.
Denmark, Japan, United States Bristol-Myers Squibb NCT06997029
Recruiting Phase 3
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Endometrial Cancer Malignant Solid Tumour

This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following platinum based chemotherapy and anti-PD-1/anti-PD-L1 therapy.

Начало: 01.08.2025 Край: 17.07.2029 Възраст: от 18 г. Treatment
Argentina, Australia, Belgium +23 AstraZeneca NCT07044336
Recruiting
Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria
Prostate Cancer Prostate Cancer (Diagnosis) Prostate Cancer (Post Prostatectomy) Prostate Cancer Patients Treated by Radiotherapy +2

The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with prostate cancer. It also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.

Начало: 21.07.2025 Край: 21.07.2026 Възраст: от 19 г.
Algeria Société Algérienne de Formation et Recherche en Oncolog NCT07484971
Recruiting Phase 3
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Non-small Cell Lung Cancer Anaplastic Lymphoma Kinase-positive

Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (NSCLC).

Начало: 17.07.2025 Край: 01.12.2029 Възраст: от 18 г. Treatment
Argentina, Australia, Belgium +21 Nuvalent Inc. NCT06765109
Recruiting Phase 3
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Prostate Cancer

The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of standard of care (SOC) (ARPI change or taxane-based chemotherapy or \[177Lu\]Lu-PSMA-617 (AAA617)) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) treated with another ARPI as last treatment and who have not been exposed to a taxane-containing chemotherapy in the mCRPC setting nor have received any prior PSMA-targeting radioligand therapy.

Начало: 01.07.2025 Край: 04.11.2032 Възраст: 18–100 г. Diagnostic
Australia, Brazil, China +8 Novartis Pharmaceuticals NCT06855277
Recruiting Phase 2
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Low-grade NMIBC FGFR Gene Amplification FGFR Gene Alterations FGFR3 Gene Alteration +2

Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC

Начало: 27.06.2025 Край: 01.09.2028 Възраст: от 18 г. Treatment
Australia, Italy, Spain +1 Tyra Biosciences, Inc NCT06995677
Recruiting
A Novel Approach to Manage Symptoms of Narcolepsy and Idiopathic Hypersomnia
Idiopathic Hypersomnia Narcolepsy Type 1 (NT 1) Narcolepsy Type 2 (NT2)

The aim of this project is to learn about how a change in diet will affect sleepiness, quality of life and metabolic health in people living with narcolepsy and idiopathic hypersomnia. The dietary changes we will be testing are well researched and safe in a wide range of patient groups (such as in obesity, type one and two diabetes, cancer and dysfunction related to the nervous system) but has not been researched in conditions of hypersomnolence such as narcolepsy and idiopathic hypersomnia. It is important to test adjunct therapies and lifestyle changes such as dietary interventions to ensure that people living with hypersomnolence have a range of options in addition to medications, to improve their health. If effective, this project will be tested in more people and may become a part of routine patient care. These dietary approaches have been shown to improve health and quality of life in people living with chronic pain, neurological conditions such as epilepsy and have been shown to be safe in these populations as well as people living with type one diabetes. This is a new area of research for people living with hypersomnolence.

Начало: 23.06.2025 Край: 01.06.2026 Възраст: от 18 г. Treatment
Australia University of Sydney NCT07006233
Recruiting Phase 2
A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer
Colorectal Cancer

The aim of Neo-POLEM is to determine the rate of Major Pathological Response (MPR) of \

Начало: 16.06.2025 Край: 31.01.2029 Възраст: от 18 г. Treatment
Australia, United Kingdom University of Southampton NCT06692959
Recruiting Phase 1/2
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed
Gastrointestinal Neoplasms

This study will check how well a new medicine, GSK5764227, works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.

Начало: 11.06.2025 Край: 23.06.2028 Възраст: от 18 г. Treatment
Australia, Belgium, Brazil +11 GlaxoSmithKline NCT06885034
Recruiting Phase 1/2
Adding IL-2 to Tebentafusp to Eradicate Cancer Progression
Uveal Melanoma Metastatic Uveal Melanoma Metastatic Uveal Melanoma in the Liver

A recent clinical trial found that after 36 months, patients taking tebentafusp had a median survival of 21.6 months, compared to 16.9 months for those in the control group. Since recruitment for tebentafusp in metastatic uveal melanoma (mUM) has ended, a new trial is starting to test whether adding IL-2 can help overcome resistance to tebentafusp and improve its effectiveness. This study aims to answer: 1. Can combining tebentafusp with IL-2 improve tumor response and overall survival? 2. What are the benefits and side effects of this combination therapy? All participants will receive both IL-2 and tebentafusp in a 28-day treatment cycle. The dosing schedule is as follows: Cycle1: Day1-3 IL-2 Day4 Tebentafusp Day 10 IL-2 Day 11 Tebentafusp Day 17 IL-2 Day 18 Tebentafusp Day 24 IL-2 Day 25 Tebentafusp Cycle 2 \& thereafter Day 1 IL-2 Day 2 Tebentafusp Day 8 IL-2 Day 9 Tebentafusp Day 15 IL-2 Day 16 Tebentafusp Day 22 IL-2 Day 23 Tebentafusp

Начало: 01.06.2025 Край: 01.09.2027 Възраст: от 18 г. Treatment
Australia St Vincent's Hospital, Sydney NCT07063875
Recruiting Phase 1/2
A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer
Gastric Cancer Adenocarcinoma Metastatic Gastroesophageal Adenocarcinoma

A first-in-human study using BDC-4182 as a single agent in gastric and gastroesophageal cancers

Начало: 26.05.2025 Край: 01.05.2029 Възраст: от 18 г. Treatment
Australia, South Korea, Taiwan Bolt Biotherapeutics, Inc. NCT06921837
Recruiting Phase 3
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
Urinary Bladder Neoplasms Immune Checkpoint Inhibitors Methotrexate Vinblastine +3

The Phase IIIb NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with investigator-selected cisplatin-based neoadjuvant chemotherapy (either ddMVAC or gemcitabine/cisplatin) in a clinical practice setting.

Начало: 15.05.2025 Край: 31.10.2028 Възраст: от 18 г. Treatment
Australia, Brazil, Canada +4 AstraZeneca NCT06960577
Recruiting Phase 1/2
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA
Prostate Cancer

This Phase I/II open-label trial aims to evaluate the safety and efficacy of the herbal supplement INM176 in patients with a history of prostate cancer or low-risk disease under active surveillance. The study will determine the recommended Phase II dose (RP2D) and assess the efficacy of INM176 in stabilizing or decreasing plasma PSA levels in post-radical prostatectomy (RP) and post-radiation therapy (RT) patients with rising PSA levels.

Начало: 07.05.2025 Край: 01.05.2028 Възраст: от 40 г.
United States Milton S. Hershey Medical Center NCT06600698
Recruiting Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Carcinoma, Non-Small-Cell Lung

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation

Начало: 24.04.2025 Край: 30.04.2032 Възраст: от 18 г. Treatment
Argentina, Australia, Belgium +30 Mirati Therapeutics Inc. NCT06875310
Recruiting Phase 1
A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
Metastatic Colorectal Cancer

The primary objective of this study is to demonstrate equivalence of pharmacokinetic properties, and comparability of safety and immunogenicity parameters of RPH-030 and Vectibix® following a single (first) intravenous administration to patients with mCRC with wild-type RAS genes as 1-line therapy in combination with FOLFIRI. The additional objective is to perform a pilot evaluation of the efficacy of RPH-030 and Vectibix® following a single (first) intravenous administration to patients with mCRC with wild-type RAS genes as 1-line therapy in combination with FOLFIRI.

Начало: 17.04.2025 Край: 01.08.2028 Възраст: от 18 г.
Russia R-Pharm NCT07543744
1 … 36 37 38 39 40 … 88